PubMed=2155676; DOI=10.1182/blood.V75.6.1311.1311
Ford R.J. Jr., Goodacre A., Ramirez I., Mehta S.R., Cabanillas F.
Establishment and characterization of human B-cell lymphoma cell lines using B-cell growth factor.
Blood 75:1311-1318(1990)

PubMed=20664054; DOI=10.1182/blood-2009-12-257378; PMCID=PMC2981542
Pham L.V., Tamayo A.T., Li C.-P., Bueso-Ramos C.E., Ford R.J. Jr.
An epigenetic chromatin remodeling role for NFATc1 in transcriptional regulation of growth and survival genes in diffuse large B-cell lymphomas.
Blood 116:3899-3906(2010)

PubMed=20889926; DOI=10.1182/blood-2010-06-290437; PMCID=PMC3037744
Pham L.V., Fu L.-C., Tamayo A.T., Bueso-Ramos C.E., Drakos E., Vega-Vazquez F., Medeiros L.J., Ford R.J. Jr.
Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-kappaB-inducing kinase while activating both canonical and alternative nuclear factor-kappaB pathways.
Blood 117:200-210(2011)

PubMed=29416618; DOI=10.18632/oncotarget.20378; PMCID=PMC5787470
Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C., Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr., Pham L.V.
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Oncotarget 9:346-360(2018)

PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004
Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H., Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Clin. Cancer Res. 24:3967-3980(2018)